CoChat
Sign Up
Cited by 209Rheumatoid Arthritis Research and TherapiesNatural Compounds in Disease TreatmentAutoimmune and Inflammatory Disorders Research

Targeting monocytes/macrophages in the treatment of rheumatoid arthritis

Davignon, J.-L., Hayder, M., Baron, M., Boyer, J.-F., Constantin, A., Apparailly, F., Poupot, R., Cantagrel, A.·2013·Rheumatology
DOI 10.1093/rheumatology/kes304
Open this paper in CoChat — free account

Abstract

Biotherapies have revolutionized the treatment of RA. However, much work is needed to understand all the mechanisms of these biotherapies, and alternatives are needed to circumvent adverse effects and the high cost of these long-lasting treatments. In this article we outline some of the approaches we have used to target monocytes/macrophages as major components of inflammation and bone homeostasis. We also discuss how anti-TNF-α antibodies target monocytes/macrophages in the complex mechanisms contributing to inhibition of inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kes304

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Therapeutic modalities targeting pathogenic cytokines such as IL-1 and TNF are already in widespread clinical use.

    “Therapeutic modalities targeting pathogenic cytokines such as IL-1 and TNF are already in widespread clinical use (Davignon et al., 2013).”

    From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Davignon et al., 2013

    The Introduction describes TNF-blocking therapies as a major tool in rheumatoid arthritis treatment, and the Discussion lists therapies targeting both TNF and IL-1. The paper does not establish that IL-1-targeting therapies, specifically, are in widespread clinical use. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 105

  1. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arth- ritis. Ann Rheum Dis 2010;69:1898906.
  2. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:2447.
  3. Stoll JG, Yasothan U. Rheumatoid arthritis market. Nat Rev Drug Discov 2009;8:6934.
  4. Kopf M, Bachmann MF, Marsland BJ. Averting inflam- mation by targeting the cytokine environment. Nat Rev Drug Discov 2010;9:70318.
  5. Buch MH, Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011;23: 24551.
  6. Gordon S, Taylor PR. Monocyte and macrophage het- erogeneity. Nat Rev Immunol 2005;5:95364.
  7. Liote F, Boval-Boizard B, Weill D, Kuntz D, Wautier JL. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expres- sion, and cytokine release. Clin Exp Immunol 1996;106: 139.
  8. Torsteinsdottir I, Arvidson NG, Hallgren R, Hakansson L. Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids. Clin Exp Immunol 1999; 115:55460.
  9. Swirski FK, Nahrendorf M, Etzrodt M et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:6126.
  10. Burmester GR, Locher P, Koch B et al. The tissue archi- tecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens. Rheumatol Int 1983;3:17381.
  11. Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther 2007;9:224.
  12. Stuhlmuller B, Ungethum U, Scholze S et al. Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum 2000; 43:77590.
  13. Kawanaka N, Yamamura M, Aita T et al. CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum 2002;46:257886.
  14. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. Cd14 is an acute-phase protein. J Immunol 2004;172: 44709.
  15. Yu S, Nakashima N, Xu BH et al. Pathological significance of elevated soluble CD14 production in rheumatoid arth- ritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol Int 1998;17:23743.
  16. Bruhl H, Cihak J, Plachy J et al. Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum 2007;56:297585.
  17. Thurlings RM, Wijbrandts CA, Bennink RJ et al. Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease. PLoS One 2009;4:e7865.
  18. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292304.
  19. Nakashima T, Takayanagi H. The dynamic interplay be- tween osteoclasts and the immune system. Arch Biochem Biophys 2008;473:16671.
  20. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009;5: 66776.
  21. Sebbag M, Parry SL, Brennan FM, Feldmann M. Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997;27:62432.
  22. Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. Sci World J 2011;11:2391402.
  23. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:45361.
  24. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell acti- vation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:190715.
  25. Evans HG, Gullick NJ, Kelly S et al. In vivo activated monocytes from the site of inflammation in humans spe- cifically promote Th17 responses. Proc Natl Acad Sci USA 2009;106:62327.
  26. Brennan FM, Foey AD, Feldmann M. The importance of T cell interactions with macrophages in rheumatoid cytokine production. Curr Top Microbiol Immunol 2006;305: 17794.
  27. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6:22530.
  28. Moss ML, Jin SL, Milla ME et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:7336.
  29. Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004;279:42898906.
  30. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmem- brane protein: ramifications for the complex physiology of TNF. Cell 1988;53:4553.
  31. Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:124857.
  32. Meusch U, Rossol M, Baerwald C, Hauschildt S, Wagner U. Outside-to-inside signaling through trans- membrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 2009;60: 261221.
  33. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997;272:1670912.
  34. Hara S, Kamei D, Sasaki Y et al. Prostaglandin E syn- thases: understanding their pathophysiological roles through mouse genetic models. Biochimie 2010;92:6519.
  35. Bonventre J. Cytosolic phospholipase A2alpha reigns su- preme in arthritis and bone resorption. Trends Immunol 2004;25:1169.
  36. Presumey J, Duroux-Richard I, Courties G, Apparailly F. Cationic liposome formulations for RNAi-based validation of therapeutic targets in rheumatoid arthritis. Curr Opin Mol Ther 2010;12:32530.
  37. Rhinn H, Largeau C, Bigey P et al. How to make siRNA lipoplexes efficient? Add a DNA cargo. Biochim Biophys Acta 2009;1790:21930.
  38. Courties G, Seiffart V, Presumey J et al. In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 2010;116:350516.
  39. Schlegel A, Largeau C, Bigey P et al. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. J Control Release 2011;152:393401.
  40. Leuschner F, Dutta P, Gorbatov R et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011;29:100510.
  41. Courties G, Baron M, Presumey J et al. Cytosolic phospholipase A2alpha gene silencing in the myeloid lin- eage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis Rheum 2011;63:68190.
  42. Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 1994;269: 1305760.
  43. Levy R, Dana R, Hazan I et al. Elevated cytosolic phospholipase A(2) expression and activity in human neutrophils during sepsis. Blood 2000;95:6605.
  44. Patel MI, Singh J, Niknami M et al. Cytosolic phospholip- ase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res 2008;14:80709.
  45. Tai N, Kuwabara K, Kobayashi M et al. Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. Inflamm Res 2010;59:5362.
  46. Marusic S, Thakker P, Pelker JW et al. Blockade of cyto- solic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes develop- ment of Th1 and Th17 responses. J Neuroimmunol 2008; 204:2937.
  47. Hegen M, Sun L, Uozumi N et al. Cytosolic phospholipase A2alpha-deficient mice are resistant to collagen-induced arthritis. J Exp Med 2003;197:1297302.
  48. Raichel L, Berger S, Hadad N et al. Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis. Eur J Immunol 2008;38:290515.
  49. Bonventre JV, Huang Z, Taheri MR et al. Reduced fertility and postischaemic brain injury in mice deficient in cyto- solic phospholipase A2. Nature 1997;390:6225.
  50. Feldmann M, Maini RN. Anti-TNF therapy, from rationale to standard of care: What lessons has it taught us? J Immunol 2010;185:7914.
  51. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011;25:54967.
  52. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, func- tion and interaction with anti-TNF agents. Rheumatology 2010;49:121528.
  53. Friedmann E, Hauben E, Maylandt K et al. SPPL2a AND SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol 2006;8:8438.
  54. Fluhrer R, Grammer G, Israel L et al. A gamma-secretase-like intramembrane cleavage of TNFalpha by the GxGD aspartyl protease SPPL2b. Nat Cell Biol 2006;8:8946.
  55. Domonkos A, Udvardy A, Laszlo L, Nagy T, Duda E. Receptor-like properties of the 26 kDa transmembrane form of TNF. Eur Cytokine Netw 2001;12:4119.
  56. Boyer JF, Balard P, Authier H et al. Tumor necrosis factor alpha and adalimumab differentially regulate CD36 ex- pression in human monocytes. Arthritis Res Ther 2007;9: R22.
  57. Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:37692.
  58. Eissner G, Kirchner S, Lindner H et al. Reverse signaling through transmembrane TNF confers resistance to lipo- polysaccharide in human monocytes and macrophages. J Immunol 2000;164:61938.
  59. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004;28:6774.
  60. Kirchner S, Boldt S, Kolch W et al. LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J Leukoc Biol 2004;75: 32431.
  61. Sekiguchi N, Kawauchi S, Furuya T et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology 2008;47:7808.
  62. Haraoui B, Cameron L, Ouellet M, White B. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:316.
  63. Mulleman D, Meric JC, Paintaud G et al. Infliximab con- centration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 2009;11: R178.
  64. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:144552.
  65. Koczan D, Drynda S, Hecker M et al. Molecular discrim- ination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008;10:R50.
  66. Lindberg J, af Klint E, Catrina AI et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006;8: R179.
  67. Lindberg J, af Klint E, Ulfgren AK et al. Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther 2006;8:R47.
  68. Lindberg J, Wijbrandts CA, van Baarsen LG et al. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS One 2010;5:e11310.
  69. Mirjafari H, Al-Husain A, Bruce IN. Cardiovascular risk factors in inflammatory arthritis. Curr Opin Lipidol 2011;22: 296301.
  70. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2011;78:17983.
  71. Greenberg JD, Kremer JM, Curtis JR et al. Tumour ne- crosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2010;70:57682.
  72. Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in pa- tients with rheumatoid arthritis. J Rheumatol 2005;32: 12138.
  73. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:12615.
  74. Allie N, Alexopoulou L, Quesniaux VJ et al. Protective role of membrane tumour necrosis factor in the host's resist- ance to mycobacterial infection. Immunology 2008;125: 52234.
  75. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010;161:19.
  76. Kleijwegt FS, Laban S, Duinkerken G et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol 2010;185: 14128.
  77. Harashima S, Horiuchi T, Hatta N et al. Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 2001;166:1306.
  78. Rossol M, Meusch U, Pierer M et al. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol 2007; 179:423948.
  79. Hayder M, Poupot M, Baron M et al. A phosphorus- based dendrimer targets inflammation and osteoclasto- genesis in experimental arthritis. Sci Transl Med 2011;3: 81ra35.
  80. Hayder M, Fruchon S, Fournie JJ, Poupot M, Poupot R. Anti-inflammatory properties of dendrimers per se. Sci World J 2011;11:136782.
  81. Fruchon S, Poupot M, Martinet L et al. Anti-inflammatory and immunosuppressive activation of human mono- cytes cby a bioactive dendrimer. J Leukoc Biol 2009;85: 55362.
  82. Poupot M, Griffe L, Marchand P et al. Design of phos- phorylated dendritic architectures to promote human monocyte activation. FASEB J 2006;20:233951.
  83. Tanaka S, Takahashi N, Udagawa N et al. Macrophage colony-stimulating factor is indispensable for both prolif- eration and differentiation of osteoclast progenitors. J Clin Invest 1993;91:25763.
  84. Paniagua RT, Chang A, Mariano MM et al. c-FMS-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. Arthritis Res Ther 2010;12:R32.
  85. Dewar AL, Cambareri AC, Zannettino AC et al. Macrophage colony-stimulating factor receptor c-FMS is a novel target of imatinib. Blood 2005;105:312732.
  86. Fitter S, Dewar AL, Kostakis P et al. Long-term imatinib therapy promotes bone formation in cml patients. Blood 2008;111:253847.
  87. Conway JG, Pink H, Bergquist ML et al. Effects of the cFMS kinase inhibitor 5-(3-methoxy-4- ((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. J Pharmacol Exp Ther 2008;326:4150.
  88. Conway JG, McDonald B, Parham J et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005;102:1607883.
  89. Ohno H, Uemura Y, Murooka H et al. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol 2008;38:28391.
  90. Kitaura H, Zhou P, Kim HJ et al. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005; 115:341827.
  91. Kimura K, Kitaura H, Fujii T, Hakami ZW, Takano- Yamamoto T. Anti-c-FMS antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo. FEMS Immunol Med Microbiol 2012;64:21927.
  92. Toh M-L, Bonnefoy J-Y, Accart N et al. Colony stimu- lating factor 1 receptor inhibition has anti-inflammatory and potent early onset bone and cartilage protective effects. Arthritis Rheum 2011;63:S444.
  93. Lenzo JC, Turner AL, Cook AD et al. Control of macro- phage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation. Immunol Cell Biol 2012;90:42940. 100
  94. MacDonald KP, Palmer JS, Cronau S et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue-and tumor-associated macrophages but does not inhibit inflammation. Blood 2010;116:395563. 101
  95. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arth- ritis: exacerbation of disease by m-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol 2000;68:14450. 102
  96. Khoury M, Louis-Plence P, Escriou V et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 2006;54: 186777. 105
  97. Caminade AM, Turrin CO, Majoral JP. Dendrimers and DNA: combinations of two special topologies for nanomaterials and biology. Chemistry 2008;14: 742232. 106
  98. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 2010;15: 17185. 107
  99. McGowan I, Gomez K, Bruder K et al. Phase 1 rando- mized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011;25:105764. 108
  100. Tyssen D, Henderson SA, Johnson A et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 2010;5:e12309. 109
  101. Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70: 90920. 110
  102. van de Veerdonk FL, Lauwerys B, Marijnissen RJ et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011;63:150716. 111
  103. Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010;107:465863. 112
  104. Vincent C, Nogueira L, Clavel C, Sebbag M, Serre G. Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 2005;38:1724. 113
  105. Uysal H, Nandakumar KS, Kessel C et al. Antibodies to citrullinated proteins: molecular interactions and arthri- togenicity. Immunol Rev 2010;233:933.

Cited by

Sorted by citations

Authors
Davignon, J.-L., Hayder, M., Baron, M., Boyer, J.-F., Constantin, A., Apparailly, F., Poupot, R., & Cantagrel, A.
Affiliations
  • Inserm (FR)
  • Centre National de la Recherche Scientifique (FR)
ORCID
Venue
Rheumatology
Publisher
Oxford University Press (OUP)
Published
2012-11-30
Volume
52
Issue
4
Pages
590-598
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
DOI
10.1093/rheumatology/kes304
OpenAlex
W2113113446
Cited by
209
References
6
Citations by year
2026: 4 · 2025: 7 · 2024: 11 · 2023: 17 · 2022: 15 · 2021: 19 · 2020: 12 · 2019: 18 · 2018: 20 · 2017: 25 · 2016: 22 · 2015: 17 · 2014: 17 · 2013: 5
FWCI
1.87
Type
journal article
Language
en
Open access
closed
Locations
  • Lara D. Veeken (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords
rheumatoid arthritis, monocytes, macrophages, anti-TNF-alpha antibody, inflammation, bone homeostasis, biologic therapy
MeSH terms
Animals, Arthritis, Rheumatoid, Humans, Macrophages, Monocytes, Tumor Necrosis Factor-alpha, Gene Silencing, RNA, Small Interfering, Dendrimers, Group IV Phospholipases A2, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review